New Medicines for UnderservedGut-Brain Axis Disorders
Bioactive, human-equivalent oligosaccharides with the potential to be transformative new medicines by modulating the microbiome and immune system.Our Focus
We are a venture capital-backed, clinical-stage company pioneering the development of human-equivalent, bioactive compounds as new medicines, initially focused on oligosaccharides found in human milk. Our pipeline of candidates modulates the gut-brain axis directly through the immune system, enteric nervous system, and indirectly by modulating the gut microbiome and metabolome.
We believe human-identical oligosaccharides have the potential to be differentiated and transformative new medicines due to their safety and multiple beneficial mechanisms of action enabling them to be a solution for patients underserved by conventional pharmaceutical approaches – who collectively represent the majority of people suffering from chronic inflammatory diseases and disorders of the gut-brain axis.
We are creating a new breed of biotech company where the growth of the company is inextricably linked to the growth of the individuals contributing to the organization. As such Intrinsic Medicine seeks individuals who are committed to their continued evolution, both personally and professionally. Our culture is built upon an 80/20 work style with a focus on outcomes to foster self-awareness and relational competency to drive meaningful interactions and value creation. These two skills increase the fidelity of the information upon which the company makes decisions, as well as the integrity and creative force of the company.
Human Milk Oligosaccharides as Medicine
R & D Pipeline
An industry veteran with a unique combination of leadership experience across unlikely disciplines with a desire to innovate a culture aligned with the medicines we are developing.
Pediatric gastroenterologist with a passion for medicines with broad potential to modulate the gut microbiome and be translated to both adults and children.
He practiced as an attorney in the merges & acquisition practice of Davis, Polk and Wardwell, an international law firm headquartered in New York City
Dave has over 30 years of experience in clinical development spanning pharmaceutical, biotech, and medical devices in the therapeutic areas.
A business leader inspired by visionary healthcare with a motivation to scale organizations by finding and maintaining balance in the disorganization inherently produced by company growth and development.MORE INFO
Scientific Advisory Board
To support the research, preclinical and clinical development of our OM candidates, we have assembled an SAB with extensive expertise in the biology of HMOs, understanding of inflammatory conditions and the scaled synthetic-biology manufacturing of HMOs.
Angela Christiano, PhD
John McCoy, PhD
David Newburg, PhD
Ardythe Morrow, PhD
Medical Advisory Board
OM002 Irritable Bowel Syndrome Medical Advisory Board
Brian Lacy, MD, PhD
Nicholas Talley, MD, PhD
Anthony Lembo, MD
Purna Kashyap, MB BS, PhD
Medical Advisory Board
OM001 Medical Advisory Board
Daniel Lovell, M.D.
Steve Hughes, M.D.
Glycosyn is a pioneer in the synthetic biology that has enabled the commercial-scale production of HMOs to supply the infant formula market, enabling clinical supply of OM002, OM001 and OM003. In addition, the scientific founders of Glycosyn are world experts in human milk oligosaccharides who invented the key intellectual property covering OM002 (2’FL) for the treatment of Irritable Bowel Syndrome and Inflammatory Bowel Disease to which we have an exclusive therapeutic license through this collaboration.
Arpeggio is a machine learning transcriptomics company focused on understanding biology differently through measuring active transcription of RNA. Our collaboration was formed in 2020 and we have exclusive rights to their platform for the characterization of HMOs to elucidate potential therapeutic mechanism in context of disease states. Through this collaboration we have already uncovered biology at the transcription level not yet observed with HMOs in the context of disease models.
News & Press Releases
Sequi eos quisquam repudiandae iusto quia commodi illum quia itaque. Omnis praesentium quaerat. Non repellendus laborum est. Quae doloremque aspernatur culpa rerum. Vero et consequat
Animi molestiae consectetur iure esse facere est in ipsa. Iste in a. Repellendus laborum odio ea. Laboriosam numquam quasi voluptas quisquam molestiae doloremque placeat voluptate. Voluptate pariatur optio ipsam. Neque necessitat
Dolor beatae est iste molestiae soluta vel aspernatur. Officia molestiae excepturi voluptas aut voluptas. Cumque quis quis accusantium. Facere voluptatem repellendus aperiam molestiae aspernatur vel eos. Autem est iste distinctio in. Et ut vel aut quia. Quia omnis ipsam. Architecto accus